Teladoc Health Announces Board and Executive Changes
Ticker: TDOC · Form: 8-K · Filed: Jul 5, 2024 · CIK: 1477449
| Field | Detail |
|---|---|
| Company | Teladoc Health, Inc. (TDOC) |
| Form Type | 8-K |
| Filed Date | Jul 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: TDOC
TL;DR
Teladoc shake-up: board members out, new exec comp plans in.
AI Summary
Teladoc Health, Inc. announced on June 28, 2024, changes in its board of directors and executive compensation. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may impact future performance.
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2 Manhattanville Road Suite 203 Purchase, NY 10577 (address) — Principal executive offices
FAQ
What specific roles have been affected by the departure of certain officers?
The filing indicates the departure of certain officers but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in this summary.
What are the key details of the updated compensatory arrangements?
The filing notes updates to compensatory arrangements for certain officers but does not provide specific details in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 28, 2024.
What is the principal executive office address for Teladoc Health, Inc.?
The principal executive office is located at 2 Manhattanville Road Suite 203 Purchase, NY 10577.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-07-05 16:05:09
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha
Filing Documents
- tdoc-20240628.htm (8-K) — 22KB
- 0001477449-24-000168.txt ( ) — 145KB
- tdoc-20240628.xsd (EX-101.SCH) — 2KB
- tdoc-20240628_lab.xml (EX-101.LAB) — 22KB
- tdoc-20240628_pre.xml (EX-101.PRE) — 13KB
- tdoc-20240628_htm.xml (XML) — 3KB
From the Filing
tdoc-20240628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 28, 2024, Teladoc Health, Inc. (the "Company") terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024. Mr. Kornwasser will remain employed with the Company as Advisor to the Chief Executive Officer until August 2, 2024. Mr. Kornwasser will receive the payments and benefits provided under his Executive Employment Agreement with the Company, dated October 24, 2022. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 5, 2024 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary